Five Presentations, One Leading Innovation: Humacyte's Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026GlobeNewsWire • Wednesday
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial AdoptionGlobeNewsWire • Tuesday
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026GlobeNewsWire • Monday
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 11/06/26
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026GlobeNewsWire • 11/03/26
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026GlobeNewsWire • 11/02/26
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 10/30/26
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered TissuesGlobeNewsWire • 10/28/26
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months SoonerGlobeNewsWire • 10/23/26
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 10/19/26
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by HospitalsGlobeNewsWire • 10/15/26
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 10/13/26
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 10/06/26
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul KuznikGlobeNewsWire • 09/28/26
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 09/18/26
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?Zacks Investment Research • 09/17/26
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/10/26
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 MonthsGlobeNewsWire • 09/09/26
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMABusiness Wire • 09/04/26
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA DiscussionsGlobeNewsWire • 08/24/26